3SOF

Nice DAY. Looks like a prosperous company for the next 6 months.
The stock is looking a little over bought right now.
I think it may need to pause a bit.

Volume: 7,312,028
Avg Vol (3m): 1,453,600

Support @ $4.69...4.20...4.00
Resistance @ $6.24....see 3 year chart below.

Recent CandleStick Analysis
Today a Long White Candlestick was formed. This shows that the prices advanced significantly from open to close during the day under strong buying pressure.

Technicals
MACD is Bullish
Stochastic is Bullish
Record Price High
Most Actives
Percentage Gainer

Last Price Quote is:
27.65%above 13-day EMA
46.44%above 50-day EMA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $180.71 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/07/2006
Last Analyst Rating: Sell

Another good looking day for this rocket.
Nice volume.
Volume: 6,644,941
Avg Volume (3m): 1,453,600

Today a Long White Candlestick was formed. This shows that the prices advanced significantly from open to close during the day under strong buying pressure.

Support @ $5.49...4.51...4.21
Resistance @ $6.24

Technicals
MACD is Bullish
Stochastic is Bullish
Record Price High
Most Actives
Percentage Gainer

Last Price Quote is:
43.31%above 13-day EMA
64.40%above 50-day EMA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $237.71 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/07/2006
Last Analyst Rating: Sell

hi,
news just out!

AVI BioPharma Reports Confirmation of Efficacy against Influenza Strains
Friday January 20, 9:00 am ET 
NEUGENE Antisense Efficacy against Influenza Strains, Including Avian Influenza, to Lead to IND Filing with the FDA


PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 20, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News) today announced confirmation from three independent laboratories of NEUGENE® antisense efficacy in preclinical experiments against multiple strains of influenza, including avian influenza strain H5N1.
Dr. P. Puthavathana at Mahidol University in Bangkok, Thailand, confirmed NEUGENE antisense efficacy against an H5N1 viral isolate in her assay system.
Dr. Darwyn Kobasa at the Public Health Agency of Canada in Winnipeg, Manitoba, completed an initial dose-response study in cell culture demonstrating NEUGENE efficacy against both the H1N1 and H3N2 strains.
Dr. Manoj Pastey at Oregon State University in Corvallis, Ore., confirmed efficacy using the same NEUGENE antisense agents against the H7N7 and H3N8 strains.
Taken together, these data confirm efficacy observed with the H1N1 strain previously reported from Drs. Jianzhu and Chen Qin Ge at Massachusetts Institute of Technology in Boston and now represent positive reports from four laboratories using different endpoints and methodologies.

"These confirmations validate our approach to blocking replication of influenza viruses. We now believe that a single NEUGENE drug could be effective against most influenza subtypes, including the H5N1 avian strain," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "By targeting regions of the viral genetic code that are common to all influenza A subtypes, we expect that our NEUGENE drugs will be effective against avian flu and the far more common influenza A viruses, which kill an average of 35,000 Americans every year."

AVI is also conducting collaborative animal studies evaluating NEUGENE efficacy against influenza strains at Tulane University in New Orleans and at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) in Frederick, Maryland.

"Based on these recent findings and other results from additional studies, AVI now plans to file an Investigative New Drug (IND) application with the FDA for the treatment of influenza A virus with NEUGENE antisense drugs," said Denis R Burger, Ph.D., chief executive officer of AVI. "We feel confident in the safety, efficacy and potency of our NEUGENE drugs targeting influenza and plan to move forward into the clinical trial process later this year."

AVI's NEUGENE antisense drug development program against the influenza A virus specifically targets genetic regions of the virus that are highly conserved between six viral subtypes that cause human disease. These include three subtypes that caused pandemics in the 20th century -- the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) -- and three subtypes of avian flu that have been reported to cause disease in humans (H5N1, H7N7 and H9N2).

AVI's Antiviral Program

AVI's proprietary NEUGENE antisense drug candidates have demonstrated efficacy in preclinical studies against SARS coronavirus, West Nile virus (WNV), hepatitis C virus (HCV), dengue virus, Ebola virus, and Marburg virus. AVI has filed IND applications with the U.S. Food and Drug Administration and has ongoing clinical trials in WNV and HCV.

Showing how versatile NEUGENE drugs can be across viral subtypes, AVI demonstrated in its collaboration with the Centers for Disease Control and Prevention that NEUGENE agents are efficacious against all four immunologically distinct subtypes of the dengue virus. This outcome was achieved by targeting a highly conserved region of the dengue viral genetic code. In collaborative work with the USAMRIID targeting the Ebola virus, NEUGENE drugs protected three animal species from lethal challenges with this virus (see PloS Pathog 2(1): e1). Additional clinical development efforts targeting dengue virus and Ebola virus are planned for 2006.

The speed with which effective NEUGENE drugs can be designed and manufactured exceeds any other modern drug development timeframe. For example, NEUGENE compounds targeting SARS, WNV and Ebola were developed within days to weeks of obtaining the appropriate genetic sequences for the viruses.

AVI's Clinical Experience

AVI's NEUGENE antisense drugs have a well-defined safety record in human clinical trials. Approximately 300 patients have been dosed with NEUGENE drug candidates targeting host and viral gene targets in 12 clinical studies under multiple INDs. Five routes of administration have been employed in AVI's clinical studies, and doses up to 450 mg have been administered without a single drug-related, serious adverse event. The combination of AVI's NEUGENE chemistry with conserved viral targets that are not expressed in the human genome makes a strong case for the potential for success in the development of candidates to address influenza, including the possible emergence of a transmittable avian flu.

About Influenza A Viruses

Influenza, or flu, is a contagious respiratory illness caused by influenza viruses. On average 5 percent to 20 percent of the U.S. population is infected with the flu each year. Influenza A virus is an enveloped negative-strand RNA virus, with eight genome segments that code for 10 proteins. Influenza strains are subtyped according to the antigenic and genetic nature of their surface glycoproteins: hemagglutinin (HA or H) and neuraminidase (NA or N). Fifteen H and nine N subtypes have been identified, with three associated with widespread human disease (H1N1, H2N2 and H3N2). In addition, several subtypes of avian influenza virus -- H5N1, H7N7 and H9N2 -- can infect and cause disease in humans.

The current influenza pandemic in birds throughout Asia, Eastern Europe and Turkey is caused by the H5N1 subtype. It is thought that co-infection of humans or certain animals (such as pigs) with both H1N1 and H5N1 can lead to a reassortment or recombination of viral particles, resulting in the emergence of a virus with dangerous public health properties, namely one to which the human population has no natural immunity and which has the ability to spread easily from person to person. It is believed that emergence of avian flu by this general mechanism may have led to the worldwide pandemics of 1918, 1957 and 1968.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus and Ebola virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Up .80 in pre mkt.

Related Quotes
Sym.   Price Chg.
AVII Trade
News 5.89 0
AVI BioPharma Reports Confirmation of Efficacy against Influenza Strains; NEUGENE Antisense Efficacy against Influenza Strains, Including Avian Influenza, to Lead to IND Filing with the FDA

January 20, 2006 09:00:04 (ET)

PORTLAND, Ore., Jan 20, 2006 (BUSINESS WIRE) -- AVI BioPharma, Inc. (AVII, Trade) today announced confirmation from three independent laboratories of NEUGENE(R) antisense efficacy in preclinical experiments against multiple strains of influenza, including avian influenza strain H5N1.

-- Dr. P. Puthavathana at Mahidol University in Bangkok, Thailand, confirmed NEUGENE antisense efficacy against an H5N1 viral isolate in her assay system.

-- Dr. Darwyn Kobasa at the Public Health Agency of Canada in Winnipeg, Manitoba, completed an initial dose-response study in cell culture demonstrating NEUGENE efficacy against both the H1N1 and H3N2 strains.

-- Dr. Manoj Pastey at Oregon State University in Corvallis, Ore., confirmed efficacy using the same NEUGENE antisense agents against the H7N7 and H3N8 strains.

Taken together, these data confirm efficacy observed with the H1N1 strain previously reported from Drs. Jianzhu and Chen Qin Ge at Massachusetts Institute of Technology in Boston and now represent positive reports from four laboratories using different endpoints and methodologies.

"These confirmations validate our approach to blocking replication of influenza viruses. We now believe that a single NEUGENE drug could be effective against most influenza subtypes, including the H5N1 avian strain," said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. "By targeting regions of the viral genetic code that are common to all influenza A subtypes, we expect that our NEUGENE drugs will be effective against avian flu and the far more common influenza A viruses, which kill an average of 35,000 Americans every year."

AVI is also conducting collaborative animal studies evaluating NEUGENE efficacy against influenza strains at Tulane University in New Orleans and at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) in Frederick, Maryland.

"Based on these recent findings and other results from additional studies, AVI now plans to file an Investigative New Drug (IND) application with the FDA for the treatment of influenza A virus with NEUGENE antisense drugs," said Denis R Burger, Ph.D., chief executive officer of AVI. "We feel confident in the safety, efficacy and potency of our NEUGENE drugs targeting influenza and plan to move forward into the clinical trial process later this year."

+22.24%.......Volume @......6,080,936.....

I'm out @ 8.01. It  looks overbought now. I'll wait and watch for a pullback and possible re-entry. Good Luck to those still holding.

hi,
hit my trailing stop at 8.08
good day
maxi

09:01 ET AVI BioPharma reports confirmation of efficacy against Influenza Strains (AVII) 5.89 :Co announces confirmation from three independent laboratories of NEUGENE antisense efficacy in preclinical experiments against multiple strains of influenza, including avian influenza strain H5N1. Dr. P. Puthavathana at Mahidol University in Bangkok, Thailand, confirmed NEUGENE antisense efficacy against an H5N1 viral isolate in her assay system. Dr. Darwyn Kobasa at the Public Health Agency of Canada in Winnipeg, Manitoba, completed an initial dose-response study in cell culture demonstrating NEUGENE efficacy against both the H1N1 and H3N2 strains. "Based on these recent findings and other results from additional studies, AVI now plans to file an Investigative New Drug application with the FDA for the treatment of influenza A virus with NEUGENE antisense drugs..We feel confident in the safety, efficacy and potency of our NEUGENE drugs targeting influenza and plan to move forward into the clinical trial process later this year."

AVII is really rocking the house.

Press Release Source: AVI BioPharma, Inc.


AVI BioPharma Announces Hepatitis C Virus License Agreement with Chiron
Friday January 27, 9:00 am ET


PORTLAND, Ore.--(BUSINESS WIRE)--Jan. 27, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News), today announced that it has entered into an agreement with Chiron Corp. granting AVI a nonexclusive license to Chiron's patents and patent applications for the research, development and commercialization of antisense therapeutics against hepatitis C virus (HCV). Chiron scientists were the first to clone HCV, and the company has been granted more than 100 HCV-related patents.


The license further strengthens AVI's patent position on its HCV antisense product candidates, which are already covered by issued U.S. patent claims. AVI's lead NEUGENE® antisense compound for HCV, AVI-4065, is currently being evaluated in a multicenter exploratory safety and efficacy clinical trial in the U.S. In conjunction with the license agreement, AVI will issue Chiron shares of AVI common stock as an initial license fee payment. Other financial terms of the agreement were not disclosed.

"This agreement with Chiron positions AVI to move forward in our HCV development program with confidence and clarity around intellectual property," said Denis R. Burger, Ph.D., chief executive officer of AVI. "The addition of the HCV patents licensed from Chiron to AVI's own patents provides a solid proprietary base in the HCV field for AVI and our eventual commercial partners."

The multicenter clinical study currently underway is designed to assess the safety, tolerability, pharmacokinetics and viral response to daily subcutaneous administration of AVI-4065 among healthy volunteers and patients with chronic active HCV. AVI recently reported completion of the first phase of this study with favorable safety, tolerability and pharmacokinetic profiles and is now in the second efficacy phase of the program. Additional data are expected from this trial later in the first quarter.

The principal investigator of the clinical trial is Mark Holodniy, M.D., F.A.C.P., professor of medicine at Stanford University School of Medicine and director of the Department of Veterans Affairs Public Health Research & Consultation Program.

About Hepatitis C

Chronic HCV infection causes an inflammation of the liver that can result in the development of cirrhosis, liver cancer or liver failure. According to the World Health Organization, approximately 170 million people worldwide are chronically infected with HCV. It is the most common chronic blood-borne infection in the developed world and the leading cause of liver transplants in the U.S. The CDC estimates that approximately 3.9 million Americans have been infected with HCV, of whom 2.7 million are chronically infected.

The Hepatitis Foundation International estimates that between 8,000 and 10,000 people die annually in the U.S. from HCV-related cirrhosis or liver cancer. The current treatment for HCV, 24 to 48 weeks of therapy with pegylated interferon alpha and ribavirin, is successful in less than half of the patients infected with genotype 1 HCV, the most common form of the virus in the U.S. Furthermore, this treatment has numerous side effects, some of them severe, which makes it difficult for almost half of initially treated patients to tolerate the recommended dosages and duration of treatment.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs. AVI's lead NEUGENE antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus and Ebola virus. AVI has introduced a NEUGENE-based exon-skipping technology called ESPRIT therapy. More information about AVI is available on the company's Web site at http://www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.


Contact:
AVI Contact:
AVI BioPharma, Inc.
Michael Hubbard, 503-227-0554
[email protected]
or
Investor Contacts:
Lippert/Heilshorn & Associates Inc.
Bruce Voss or Jody Cain, 310-691-7100
[email protected] or [email protected]
or
Press Contact:
Waggener Edstrom Worldwide
Bioscience and Healthcare Practice
Jenny Moede, 503-443-7000
[email protected]

--------------------------------------------------------------------------------
Source: AVI BioPharma, Inc.

AVI BIOPHARMA INC (NasdaqNM:AVII) Delayed quote data 

Pre-Market (RT-ECN): 7.85  0.50 (6.80%) ...........

 
+6.14%......Volume @.......2,106,872
Another leg up......

I'm in from a few days ago. Stockconsultant.com has a breakout > 7.94 and target is 9.14.
Not sure how good stockconsultant is but we'll see.

The Chart.......

This should be a gapper tomorrow morning.